Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Failure
25%
Acute Heart Infarction
12%
All Cause Mortality
6%
Anemia
13%
Angiotensin
7%
Biological Marker
15%
Cardiomyopathy
8%
Chronic Kidney Failure
5%
Congestive Heart Failure
9%
Dipeptidyl Carboxypeptidase Inhibitor
6%
Disease
11%
Erythropoietin
16%
Ferric Carboxymaltose
8%
Heart Failure
100%
Heart Failure with Preserved Ejection Fraction
8%
Heart Failure with Reduced Ejection Fraction
13%
Heart Infarction
12%
Hyperkalemia
6%
Iron Deficiency
20%
Malignant Neoplasm
6%
Pathophysiology
6%
Placebo
14%
Prevalence
6%
Valsartan/Sacubitril
5%
Medicine and Dentistry
Acute Decompensated Heart Failure
14%
Amino Terminal Sequence
5%
Anemia
9%
Atrial Fibrillation
5%
Biological Marker
10%
Cardiology
10%
Cardiomyopathy
6%
Cardiovascular Disease
6%
Cardiovascular System
12%
Congestive Heart Failure
8%
Disease
10%
Ejection Fraction
15%
Erythropoietin
5%
Exercise
6%
Heart Failure
76%
Heart Failure with Preserved Ejection Fraction
14%
Heart Failure with Reduced Ejection Fraction
10%
Heart Function
8%
Heart Left Ventricle Ejection Fraction
9%
Iron Deficiency
12%
Malignant Neoplasm
8%
Oncology
6%
Pathophysiology
6%
Peripartum Cardiomyopathy
11%
Placebo
8%
Semaglutide
5%
Transthyretin
5%
Keyphrases
Acute Heart Failure
22%
Acute Myocardial Infarction
7%
All-cause Mortality
6%
Anemia
7%
BIOSTAT-CHF
5%
Cardiomyopathy
5%
Chronic Heart Failure
6%
Clinical Outcomes
5%
Comorbidity
6%
Confidence Interval
8%
Ferric Carboxymaltose
7%
Hazard Ratio
6%
Heart Failure
36%
Heart Failure Hospitalization
9%
Heart Failure Patients
9%
Heart Failure with Preserved Ejection Fraction (HFpEF)
16%
High Risk
5%
Hyperkalemia
5%
Iron Deficiency
15%
Left Ventricular Ejection Fraction
6%
Myocardial Infarction
6%
Paradise
5%
Patients with Heart Failure
17%
Peripartum Cardiomyopathy
9%
Placebo
7%
Preserved Ejection Fraction
6%
